Table 3 Clinical outcome of Hymenoptera field stings during and after VIT
No reaction | Anaphylactic reaction | Total | |||
|---|---|---|---|---|---|
I (mild) | II (moderate) | III (severe) | |||
All stings | 368 (92.9%) | 13 (3.3%) | 13 (3.3%) | 2 (0.5%) | 396 (100%) |
Mono sensitized patients | 156 (94.0%) | 6 (3.6%) | 4 (2.4%) | 0 (0%) | 166 (100%) |
Double sensitized patients | 212 (92.2%) | 7 (3.0%) | 9 (3.9%) | 2 (0.9%) | 230 (100%) |
Stings during VIT | 145 (96.7%) | 3 (2.0%) | 2 (1.3%) | 0 (0%) | 150 (100%) |
Mono sensitized patients | 67 (98.5%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 68 (100%) |
Double sensitized patients | 78 (95.1%) | 2 (2.4%) | 2 (2.4%) | 0 (0%) | 82 (100%) |
Stings after VIT discontinuation | 223 (90.7%) | 10 (4.1%) | 11 (4.5%) | 2 (0.8%) | 246 (100%) |
Mono sensitized patients | 89 (90.8%) | 5 (5.1%) | 4 (4.1%) | 0 (0%) | 98 (100%) |
Double sensitized patients | 134 (90.5%) | 5 (3.4%) | 7 (4.7%) | 2 (1.4%) | 148 (100%) |